CD115 is also known as c-fms, marcophage colony stimulating factor receptor, or CSF-1R. It exists in immature (gp130 c-fms) and mature (gp150 c-fms) forms. CSF-1R exhibits an intrinsic tyrosine-specific protein kinase activity. It is expressed on the cells of the mononuclear phagocyte lineage. CSF-1R is an integral transmembrane glycoprotein consisting of a 512 amino acid extracellular domain that includes the CSF-1 binding site, a single 25 amino acid membrane-spanning segment, and a 435 amino acid cytoplasmic portion that includes the tyrosine kinase domain.
A DNA sequence encoding the extracellular domain of human M-CSF R (c-fms) (aa residue 1-512) (Coussens, L. et al., 1986, Nature 320:277-280) was fused to the carboxy-terminal 6X histidine tagged Fc region of human IgG1 via a ploypeptide linker. The chimeric protein was expressed in a mouse myeloma cell line, NSO. Recombinant human M-CSF R/Fc chimera is a disulfide-linked homodimer. Each monomeric subunit, generated after the removal of a 19 residue signal peptide, contains 737 amino acid residues with a calculated molecular mass of 81kD. As a result of glycosylation, the monomeric subunits migrate as an approximately 150kD protein in SDS-PAGE under reducing conditions.
Human Macrophage Colony Stimulating Factor R/Fc Chimera M-CSF receptor, the product of the c-fms proto-oncogene, is a member of the type III subfamily of receptor tyrosine kinases thatalso includes Flt-3, the receptor for SCF, and the a and b receptors for PDGF. These receptors are characterized by the presence of five immunoglobulin-like domains in their extracellular region and a split kinase domain in their intracellular region. M-CSF binding induces receptor homodimerization, resulting in transphosphorylation of specific cytoplasmic tyrosine residues and signal transduction. The c-fms proto-oncogene has been mapped to chromosome 5 at band 5q33.3, in close proximity to the gene for the PDGF b receptor. M-CSF receptor is expressed primarily on cells of the monocyte/macrophage lineage and in various tissues ofthe developing placenta Human M-CSF receptor cDNA encodes a 972 amino acid residue type I membrane protein with a 23 aa residue putative signal peptide, a 489 aa residue extracellular region containing the ligand-binding domain, a 25 aa residue transmembrane domain and a435 aa residue cytoplasmic domain. Activators of protein kinase C has been shown to induce the proteolytic cleavage of M-CSF receptor from the cell surface, resulting in the release of the functional ligand-binding extracellular domain. Recombinant soluble M-CSF R/Fc chimera binds M-CSF with high affinity and is a potent M-CSF antagonist (Sherr, C.J. 1990, Blood 75:1-12;Hamilton, J.A., 1997, J. Leukoc. Biol. 62:145-155).
Source:Mouse myeloma cell line, NS0-derived
Human M-CSF R (Ile20-Glu512), DIEGRMD, human IgG1 (Pro100-Lys330), 6His-Tag
Activity:Measured by its ability to inhibit the M-CSF induced proliferation of NFS-60 mouse myelogenous leukemia lymphoblast cells. The ED50 for this effect is typically 0.004-0.012ug/ml in the presence of 1ng/ml of rhM-CSF.
Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months after receipt at -20°C. Reconstitute with sterile PBS, 0.1% HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
仕様
Size：100ug
Source Antigen：Recombinant, NS0 cells
Grade：Highly Purified
Purity：≥95%, as determined by SDS-PAGE under reducing conditions and visualized by silver stain. Endotoxin: ≤0.1EU/ug (LAL)
Form：Supplied as a lyophilized powder in PBS, pH 7.4, BSA. Reconstitute with 1ml sterile PBS, 0.1% HSA or BSA.
